Abstract
Blister formation in skin and mucous membranes results from a loss of cell-cell or cell-matrix adhesion and is a common outcome of pathological events in a variety of conditions, including autoimmune and genetic diseases, viral and bacterial infections, or injury by physical and chemical factors. Autoantibodies against structural components maintaining cell-cell and cell-matrix adhesion induce tissue damage in autoimmune blistering diseases. Detection of these autoantibodies either tissue-bound or circulating in serum is essential to diagnose the autoimmune nature of disease. Various immunofluorescence methods as well as molecular immunoassays, including enzyme-linked immunosorbent assay and immunoblotting, belong to the modern diagnostic algorithms for these disorders. There is still a considerable need to increase awareness of the rare autoimmune blistering diseases, which often show a severe, chronic-relapsing course, among physicians and the public. This review article describes the immunopathological features of autoimmune bullous diseases and the molecular immunoassays currently available for their diagnosis and monitoring.
Keywords: Autoantibodies, autoantigens, basement membrane, desmosome, ELISA, extracellular matrix, hemidesmosome, immunoassay, immunoblotting, immunofluorescence microscopy.
Current Molecular Medicine
Title:Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Volume: 14 Issue: 1
Author(s): J.V. Otten, T. Hashimoto, M. Hertl, A.S. Payne and C. Sitaru
Affiliation:
Keywords: Autoantibodies, autoantigens, basement membrane, desmosome, ELISA, extracellular matrix, hemidesmosome, immunoassay, immunoblotting, immunofluorescence microscopy.
Abstract: Blister formation in skin and mucous membranes results from a loss of cell-cell or cell-matrix adhesion and is a common outcome of pathological events in a variety of conditions, including autoimmune and genetic diseases, viral and bacterial infections, or injury by physical and chemical factors. Autoantibodies against structural components maintaining cell-cell and cell-matrix adhesion induce tissue damage in autoimmune blistering diseases. Detection of these autoantibodies either tissue-bound or circulating in serum is essential to diagnose the autoimmune nature of disease. Various immunofluorescence methods as well as molecular immunoassays, including enzyme-linked immunosorbent assay and immunoblotting, belong to the modern diagnostic algorithms for these disorders. There is still a considerable need to increase awareness of the rare autoimmune blistering diseases, which often show a severe, chronic-relapsing course, among physicians and the public. This review article describes the immunopathological features of autoimmune bullous diseases and the molecular immunoassays currently available for their diagnosis and monitoring.
Export Options
About this article
Cite this article as:
Otten J.V., Hashimoto T., Hertl M., Payne A.S. and Sitaru C., Molecular Diagnosis in Autoimmune Skin Blistering Conditions, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/15665240113136660079
DOI https://dx.doi.org/10.2174/15665240113136660079 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Endoglin-Targeted Cancer Therapy
Current Drug Delivery Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets SJSZ Glycoprotein (38 kDa) Inhibits Cell Cycle and Oxidative Stress in N-Methyl-N`- nitro-N-nitrosoguanidine-induced ICR Mice
Anti-Cancer Agents in Medicinal Chemistry Liposomal Formulation for Dermal and Transdermal Drug Delivery: Past, Present and Future
Recent Patents on Drug Delivery & Formulation Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Molecular Mechanism of Inhibition of Polysialyltransferase Domain (PSTD) by Heparin
Current Topics in Medicinal Chemistry Conserved Molecular Players for Axon Guidance and Angiogenesis
Current Protein & Peptide Science Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Current Drug Discovery Technologies Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry In Search of the Most Suitable Lentiviral shRNA System
Current Gene Therapy αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology
Current Topics in Medicinal Chemistry Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities
Anti-Cancer Agents in Medicinal Chemistry Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives
Current Medicinal Chemistry Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets